CSF and blood levels of APP-derived proteins seem not to be reliable markers of disease activity or progression since their levels are largely dependent on complex regulatory metabolic processes which could be highly variable in a complex and heterogenous disease such as MS. Here, APP is linked to myeloid sarcoma.